Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia
· Delayed Price · Currency is AUD 3.580
+0.110 (3.17%)
At close: Mar 6, 2026
Clarity Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2018 |
| Other Revenue | 10.58 | 9.46 | 11.51 | 9.8 | 6.46 | 3.2 | Upgrade
|
| Revenue | 10.58 | 9.46 | 11.51 | 9.8 | 6.46 | 3.2 | Upgrade
|
| Revenue Growth (YoY) | -1.83% | -17.76% | 17.41% | 51.74% | 102.07% | 14.62% | Upgrade
|
| Gross Profit | 10.58 | 9.46 | 11.51 | 9.8 | 6.46 | 3.2 | Upgrade
|
| Selling, General & Admin | 17.72 | 11.68 | 9.94 | 4.71 | 4.61 | 3.83 | Upgrade
|
| Research & Development | 88.82 | 66.88 | 45.78 | 31.46 | 18.9 | 9.68 | Upgrade
|
| Operating Expenses | 106.54 | 78.56 | 55.72 | 36.16 | 23.51 | 13.51 | Upgrade
|
| Operating Income | -95.96 | -69.09 | -44.21 | -26.36 | -17.05 | -10.31 | Upgrade
|
| Interest & Investment Income | 6.12 | 4.76 | 2.77 | 1.86 | 0.1 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.68 | 0.45 | -0.59 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -95.52 | -63.88 | -42.03 | -24.5 | -16.95 | -10.27 | Upgrade
|
| Other Unusual Items | - | - | - | - | -6.78 | 0.05 | Upgrade
|
| Pretax Income | -95.52 | -63.88 | -42.03 | -24.5 | -23.74 | -10.22 | Upgrade
|
| Income Tax Expense | 0.72 | 0.42 | 0.3 | 0.1 | 0.02 | - | Upgrade
|
| Net Income | -96.35 | -64.3 | -42.32 | -24.6 | -23.75 | -10.22 | Upgrade
|
| Net Income to Common | -96.35 | -64.3 | -42.32 | -24.6 | -23.75 | -10.22 | Upgrade
|
| Shares Outstanding (Basic) | 343 | 319 | 273 | 260 | 248 | 176 | Upgrade
|
| Shares Outstanding (Diluted) | 343 | 319 | 273 | 260 | 248 | 176 | Upgrade
|
| Shares Change (YoY) | 13.88% | 16.86% | 5.22% | 4.81% | 40.37% | 20.54% | Upgrade
|
| EPS (Basic) | -0.28 | -0.20 | -0.15 | -0.09 | -0.10 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.20 | -0.15 | -0.10 | -0.10 | -0.06 | Upgrade
|
| Free Cash Flow | -72.59 | -54.95 | -43.74 | -27.55 | -13.53 | -7.74 | Upgrade
|
| Free Cash Flow Per Share | -0.21 | -0.17 | -0.16 | -0.11 | -0.06 | -0.04 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -906.99% | -730.16% | -384.24% | -269.00% | -263.94% | -322.65% | Upgrade
|
| Profit Margin | -910.66% | -679.45% | -367.82% | -251.03% | -367.78% | -319.77% | Upgrade
|
| Free Cash Flow Margin | -686.15% | -580.71% | -380.14% | -281.07% | -209.43% | -242.06% | Upgrade
|
| EBITDA | -95.71 | -68.91 | -44.06 | -26.26 | -17 | -10.3 | Upgrade
|
| EBITDA Margin | - | - | - | -267.97% | -263.22% | - | Upgrade
|
| D&A For EBITDA | 0.25 | 0.19 | 0.15 | 0.1 | 0.05 | 0.02 | Upgrade
|
| EBIT | -95.96 | -69.09 | -44.21 | -26.36 | -17.05 | -10.31 | Upgrade
|
| EBIT Margin | - | - | - | -269.00% | -263.94% | - | Upgrade
|
| Revenue as Reported | 13.77 | 14.68 | 14.28 | 11.66 | 6.55 | 3.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.